FILTER
FILTERED ARTICLE RESULTS
Innovation: The Industry’s Backbone
May 24, 2017
The cost of developing new drugs and cures is enormous. A delicate balance between encouraging innovation and controlling the cost of medicines has to be maintained.
Logistics and Distribution: From Factory to Patient
May 09, 2017
Consolidation and the requirements of new and personalized drugs are changing the playing field.
Paying the Price: U.S. Biopharma Industry
March 17, 2017
Slashing drug prices might benefit patients in the short term, but at what cost?
Pooling Its Force: U.S. Biopharmaceutical Industry Channels R&D Focus Amid Changing Tides
March 01, 2017
In a time of uncertainty across the board, the United States is still "going boldly” ahead, bringing us innovation and constantly adapting its business model.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
